Senti Biosciences to sell most of its business to largest shareholder Celadon Partners, reports preliminary cash of $6.5 million.

Senti Biosciences announced a definitive agreement for an affiliate of its largest stockholder, Celadon Partners, to acquire substantially all of the company's existing business and pipeline. The company did not report revenue or EPS, but provided a preliminary cash and cash equivalents balance of $6.5 million as of June 30, 2026.

Key Highlights

• Senti will remain a public company with a streamlined structure, retaining intellectual property and early-stage programs focused on its Regulator Dial™ technology platform for Rett syndrome and TIL therapies.
• Current stockholders will receive contingent value rights (CVRs) that may provide future cash payments of up to $60 million based on specific development, regulatory, and commercial milestones for its SENTI-202 candidate.
• The company reported a preliminary cash and cash equivalents balance of $6.5 million as of June 30, 2026, which, combined with additional funding, is expected to fund operations into the fourth quarter of 2026.